The present disclosure provides a group of amidine analogs and their pharmaceutically acceptable salts that are useful for treating a bacterial or fungal infection. The infection may include those infections caused by gram negative bacteria, gram positive bacteria, or fungi. Compositions, methods of synthesizing the same and methods for treating bacterial or fungal infection are disclosed herein.

The present disclosure provides a group of amidine analogs and their pharmaceutically acceptable salts that are useful for treating a bacterial or fungal infection. The infection may include those infections caused by gram negative bacteria, gram positive bacteria, or fungi. Compositions, methods of synthesizing the same and methods for treating bacterial or fungal infection are disclosed herein.

Compounds and methods for the treatment of a bacterial infection or the potentiation of an antibiotic in treating a bacterial infection are described herein.

Compounds and methods for the treatment of a bacterial infection or the potentiation of an antibiotic in treating a bacterial infection are described herein.

The present application relates to amidine substituted analogues as shown in formula I and uses thereof as an anti-inflammatory agent and/or for the treatment of an immunological disorder or of an inflammatory bowel disease including ulcerative colitis, Crohn's diseases, collagenous colitis and lymphocytic colitis. ##STR00001##

The present application relates to amidine substituted analogues as shown in formula I and uses thereof as an anti-inflammatory agent and/or for the treatment of an immunological disorder or of an inflammatory bowel disease including ulcerative colitis, Crohn's diseases, collagenous colitis and lymphocytic colitis. ##STR00001##

The present invention relates in certain aspects to the discovery of novel 2-naphthimidamide compounds that are capable of binding Type II Transmembrane Serine Proteases (TTSPs). In certain embodiments, the compounds of the invention can be used to treat or prevent Influenza A viral infection in a mammal.

The present invention relates in certain aspects to the discovery of novel 2-naphthimidamide compounds that are capable of binding Type II Transmembrane Serine Proteases (TTSPs). In certain embodiments, the compounds of the invention can be used to treat or prevent Influenza A viral infection in a mammal.

A compound having a first ligand of the following

##STR00001##

is described. Ring A represents a monocyclic aromatic group or a polycyclic aromatic group. Ring B represents a polycyclic aromatic group. Z is a carbon. Z and the right N are coordinated to a metal to form a five-membered chelate ring. R.sub.1 and R.sub.2 independently represent mono to a maximum possible number of substitutions, or no substitution.

A compound having a first ligand of the following

##STR00001##

is described. Ring A represents a monocyclic aromatic group or a polycyclic aromatic group. Ring B represents a polycyclic aromatic group. Z is a carbon. Z and the right N are coordinated to a metal to form a five-membered chelate ring. R.sub.1 and R.sub.2 independently represent mono to a maximum possible number of substitutions, or no substitution.